Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy

Acta Radiologica

Volumn 52, Issue 6, 2011, Pages 646-650

  Yan, Hongjiang ^a   Wang, Renben ^a   Zhao, Fen ^a   Zhu, Kunli ^b   Jiang, Shumei ^a   Zhao, Wei ^a   Feng, Rui ^a  

^a Department of Radiation Oncology ^*  (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Lung cancer; Metabolic tumor volume (MTV); Positron emission tomography (PET); Prognostic factors

Indexed keywords

18-F-FLUORODEOXYGLUCOSE; ACCURATE PREDICTION; FDG PET; HAZARD RATIO; HISTOLOGICAL TYPE; INDIVIDUAL RISKS; LUNG CANCER; METABOLIC TUMOR VOLUME (MTV); MULTI VARIATE ANALYSIS; NON SMALL CELL LUNG CANCER; POSITRON EMISSION; PRE-TREATMENT; PREDICTIVE PERFORMANCE; PREDICTIVE VALUES; PROGNOSTIC FACTORS; RECEIVER OPERATING CHARACTERISTICS; ROC ANALYSIS; SQUAMOUS CELL CARCINOMA; STANDARDIZED UPTAKE VALUES; TIME-DEPENDENT; TUMOR VOLUMES; UNIVARIATE ANALYSIS; VOLUMETRIC PARAMETERS;

BIOLOGICAL ORGANS; CELLS; DISEASES; METABOLISM; MULTIVARIANT ANALYSIS; PATIENT TREATMENT; POSITRONS; RATING; TUMORS;

POSITRON EMISSION TOMOGRAPHY;

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

AREA UNDER THE CURVE; ARTICLE; CANCER STAGING; COMPUTER ASSISTED DIAGNOSIS; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METHODOLOGY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SCINTISCANNING; SURVIVAL RATE; TUMOR VOLUME;

AREA UNDER CURVE; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; ROC CURVE; SURVIVAL RATE; TUMOR BURDEN;

EID: 80053073995     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1258/ar.2011.100462     Document Type: Article

References (25)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
2. Takamochi K, Oh S, Suzuki K. Prognostic evaluation of nodal staging based on the new IASLC lymph node map for lung cancer. Thorac Cardiovasc Surg 2010;58:345-9
3. UyBico SJ, Wu CC, Suh RD, et al. Lung cancer staging essentials: The new TNM staging system and potential imaging pitfalls. Radiographics 2010;30:1163-81
4. Basaki K, Abe Y, Aoki M, et al. Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: Impact of tumor volume. Int J Radiat Oncol Biol Phys 2006;64:449-54 (Pubitemid 43083431)
5. Kawaguchi T, Takada M, Kubo A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: A comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol 2010;5:620-30
6. Kim YS, Lee MK, Kim SJ, et al. Prognostic stratification using F-18 FDG PET/CT in patients with advanced stage (stage III and IV) non-small cell lung cancer. Neoplasma 2010;57:241-6
7. Hoang JK, Hoagland LF, Coleman RE, et al. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol 2008;26:1459-64
8. Cerfolio RJ, Bryant AS, Ohja B, et al. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 2005;130:151-9 (Pubitemid 40941684)
9. Sasaki R, Komaki R, Macapinlac H, et al. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non- small-cell lung cancer. J Clin Oncol 2005;23:1136-43 (Pubitemid 46202269)
10. Eschmann SM, Friedel G, Paulsen F, et al. Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? Eur J Nucl Med Mol Imaging 2006;33:263-9
11. Davies A, Tan C, Paschalides C, et al. FDG-PET maximum standardised uptake value is associated with variation in survival: Analysis of 498 lung cancer patients. Lung Cancer 2007;55:75-8 (Pubitemid 46038876)
12. Lee P, Weerasuriya DK, Lavori PW, et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys 2007;69:328-33 (Pubitemid 47380105)
13. Greco C, Rosenzweig K, Cascini GL, et al. Current status of PET/CT for tumour volume definition in radiotherapy treatment planning for non-small cell lung cancer (NSCLC). Lung Cancer 2007;57:125-34 (Pubitemid 47043188)
14. Miller TR, Grigsby PW. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys 2002;53:353-9 (Pubitemid 34522101)
15. Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32-5
16. Zheng Y, Cai T, Feng Z. Application of the time-dependent ROC curves for prognostic accuracy with multiple biomarkers. Biometrics 2006;62:279-87
17. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000;56:337-44 (Pubitemid 30422619)
18. Nestle U, Kremp S, Schaefer-Schuler A, et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. J Nucl Med 2005;46:1342-8 (Pubitemid 43733485)
19. Zasadny KR, Kison PV, Francis IR, et al. FDG-PET determination of metabolically active tumor volume and comparison with CT. Clin Positron Imaging 1998;1:123-9 (Pubitemid 128784438)
20. Biehl KJ, Kong FM, Dehdashti F, et al. 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: Is a single standardized uptake value threshold approach appropriatê J Nucl Med 2006;47:1808-12 (Pubitemid 47545003)
21. Bradley JD, Ieumwananonthachai N, Purdy JA, et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2002;52:49-57 (Pubitemid 34041565)
22. Brown R, Leung J. Glucose Transporterers and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 1999;40:556-65 (Pubitemid 29171796)
23. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007;48:932-45 (Pubitemid 46909922)
24. Boellaard R, Krak NC, Hoekstra OS, et al. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: A simulation study. J Nucl Med 2004;45:1519-27 (Pubitemid 47618506)
25. Westerterp M, Pruim J, Oyen W, et al. Quantification of FDG PET studies using standardized uptake values in multi-centre trials: Effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging 2007;34:392-404 (Pubitemid 46295349)